BFC Planning’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History
Bought
Maintained
Sold
Other funds holding IRLA
BFC Planning's IRLA Position: Q3 2026 in Review
BFC Planning increased its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 7.1% in Q3 2026, buying an estimated $27 and bringing the position to 15 shares worth $465. The position accounts for ﹤0.01% of the portfolio, ranked #3294.
BFC Planning first reported a position in IRLA in Q3 2024 and has held it in 8 quarters since. The position peaked at $10K in Q4 2025. 21 funds tracked by Wall St. Rank hold IRLA as of Q3 2026.
- BFC Planning held 15 shares of IRulya Therapeutics Inc. Common Stock worth $465 as of Q3 2026.
- BFC Planning bought 1 IRulya Therapeutics Inc. Common Stock share in Q3 2026, an estimated $27.
- IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3294 holding.
- BFC Planning first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2024 and has held it in 8 quarters since.
- BFC Planning's IRulya Therapeutics Inc. Common Stock position peaked at $10K in Q4 2025.
- 21 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.